Brookstone Capital Management Has $1.13 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Brookstone Capital Management decreased its position in Zoetis Inc. (NYSE:ZTSGet Rating) by 3.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,366 shares of the company’s stock after selling 195 shares during the period. Brookstone Capital Management’s holdings in Zoetis were worth $1,133,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Zoetis by 3.6% in the 1st quarter. BlackRock Inc. now owns 41,766,559 shares of the company’s stock valued at $7,876,755,000 after buying an additional 1,450,749 shares during the period. State Street Corp boosted its stake in Zoetis by 2.7% in the 4th quarter. State Street Corp now owns 19,994,627 shares of the company’s stock worth $4,879,289,000 after purchasing an additional 529,974 shares during the period. Alliancebernstein L.P. boosted its stake in Zoetis by 2.6% in the 4th quarter. Alliancebernstein L.P. now owns 17,663,325 shares of the company’s stock worth $4,310,381,000 after purchasing an additional 441,440 shares during the period. Bank of America Corp DE boosted its stake in Zoetis by 0.6% in the 1st quarter. Bank of America Corp DE now owns 12,775,847 shares of the company’s stock worth $2,409,397,000 after purchasing an additional 78,088 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Zoetis by 24.4% in the 1st quarter. Wellington Management Group LLP now owns 6,301,310 shares of the company’s stock worth $1,188,364,000 after purchasing an additional 1,234,738 shares during the period. Institutional investors and hedge funds own 91.05% of the company’s stock.

Zoetis Stock Down 1.1 %

Shares of ZTS opened at $151.24 on Thursday. Zoetis Inc. has a 52 week low of $150.87 and a 52 week high of $249.27. The firm has a market cap of $70.80 billion, a P/E ratio of 34.29, a price-to-earnings-growth ratio of 2.74 and a beta of 0.77. The firm’s 50-day simple moving average is $168.03 and its 200 day simple moving average is $173.80. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18.

Zoetis (NYSE:ZTSGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The company had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same quarter last year, the company posted $1.19 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. On average, analysts forecast that Zoetis Inc. will post 5.01 earnings per share for the current year.

Analysts Set New Price Targets

ZTS has been the subject of a number of research analyst reports. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. The Goldman Sachs Group cut their price target on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. Stifel Nicolaus cut their price target on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Finally, Piper Sandler started coverage on shares of Zoetis in a research report on Monday, July 11th. They set an “overweight” rating and a $205.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Moderate Buy” and an average price target of $224.00.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total transaction of $758,450.00. Following the transaction, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,145,225. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Zoetis news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total transaction of $758,450.00. Following the transaction, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,145,225. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kristin C. Peck sold 9,689 shares of the stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the sale, the chief executive officer now owns 39,743 shares in the company, valued at approximately $7,153,740. The disclosure for this sale can be found here. Insiders have sold a total of 16,501 shares of company stock worth $2,949,073 in the last quarter. Corporate insiders own 0.12% of the company’s stock.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.